BTAIQ · BioXcel Therapeutics, Inc. · Investor Relations
$0.05
0.00 (-6.25%)
At close · Oct 7
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$1.72M
Shares
31.31M
Volume · Oct 7
169.93K
Avg daily vol (3M)
6.01M
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-02-27 | BioXcel Therapeutics KOL Virtual Roundtable Day | Webcast |
| 2025-12-08 | KOL Video -Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions | Webcast |
| 2025-09-10 | Bioxcel Therapeutics SERENITY At-Home Pivotal Phase 3 Safety Trial Results | Earnings call |
| 2025-09-08 | H.C. Wainwright 27th Annual Global Investment Conference | Conference |
| 2025-08-27 | Conference call to review topline data from the SERENITY At-Home Pivotal Phase 3 trial evaluating the safety of BXCL501 | Conference |
| 2025-08-14 | H.C. Wainwright & Co. “HCW@Home” series | Webcast |
| 2025-08-12 | Canaccord Genuity 45th Annual Growth Conference | Conference |
| 2024-11-14 | Third Quarter 2024 Financial Results | Earnings call |
| 2024-10-30 | ThinkEquity Conference | Conference |
| 2024-08-13 | Canaccord Genuity 44th Annual Growth Conference | Conference |